Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure. Issue 6 (7th May 2021)

• Record Type: Journal Article
• Authors: Kobayashi, Masatake; Voors, Adriaan A.; Ouwerkerk, Wouter; Duarte, Kevin; Girerd, Nicolas; Rossignol, Patrick; Metra, Marco; Lang, Chim C.; Ng, Leong L.; Filippatos, Gerasimos; Dickstein, Kenneth; van Veldhuisen, Dirk J.; Zannad, Faiez; Ferreira, João Pedro
• Is Part Of: Clinical cardiology. Volume 44:Issue 6(2021)
• Page Start: 780
• Page End: 788
• Publication Date: 2021-05-07
• Subjects: ACE‐inhibitor -- adverse effects -- ARB -- beta‐blocker -- treatment up‐titration; Cardiology -- Periodicals; 616.12005
• DOI: 10.1002/clc.23576
• Languages: English
• ISSNs: 0160-9289

Abstract

Abstract: Background: Achieving target doses of angiotensin‐converting‐enzyme inhibitor/angiotensin‐receptor blockers (ACEi/ARB) and beta‐blockers in heart failure with reduced ejection fraction (HFrEF) is often underperformed. In BIOlogy Study to TAilored Treatment in chronic heart failure (BIOSTAT‐CHF) study, many patients were not up‐titrated for which no clear reason was reported. Therefore, we hypothesized that perceived‐risk profile might influence treatment optimization. Methods: We studied 2100 patients with HFrEF (LVEF≤40%) to compare the clinical characteristics and adverse events associated with treatment up‐titration (after a 3‐month titration protocol) between; a) patients not reaching target doses for unclear reason; b) patients not reaching target doses due to symptoms and/or side effects; c) patients reaching target doses. Results: For ACEi/ARB, (a), (b) and (c) was observed in 51.3%, 25.9% and 22.7% of patients, respectively. For beta‐blockers, (a), (b) and (c) was observed in 67.5%, 20.2% and 12.3% of patients, respectively. By multinomial logistic regression analysis for ACEi/ARB, patients in group (a) and (b) had lower blood pressure and poorer renal function, and patients in group (a) were older and had lower ejection fraction. For beta‐blockers, patients in group (a) and (b) had more severe congestion and lower heart rate. At 9 months, adverse events (i.e., hypotension, bradycardia, renal impairment, and hyperkalemia) occurred similarly among the three groups. Conclusions: Patients in whom clinicians did not give a reason why up‐titration was missed were older and had more co‐morbidities. Patients in whom up‐titration was achieved did not have excess adverse events. However, from these observational findings, the pattern of subsequent adverse events among patients in whom up‐titration was missed cannot be determined.